FDA Brief

Warning letters Drugs

FDA warning letter to

MantroForce

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

MantroForce marketed five sexual-health and prostate products as unapproved new drugs, FDA says.

What happened

FDA reviewed MantroForce’s website in May 2026 and found five products marketed with claims to treat premature ejaculation, erectile dysfunction, and prostate or urinary symptoms. FDA determined the products are drugs and new drugs (drugs needing FDA approval because they are not generally recognized as safe and effective), with no approved applications. The letter quotes product webpage labeling as evidence of intended drug use.

What FDA found

  1. The products are drugs because their labeling says they treat disease or affect body function.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. The products are new drugs because they are not generally recognized as safe and effective for their labeled uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. No FDA-approved application is in effect for any of the five products.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  4. Selling or shipping these unapproved new drugs in U.S. commerce violates the law.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  5. Website labeling shows the products are intended for drug uses.

    21 CFR 201.128

What FDA wants

Send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receipt, including corrective steps, steps to prevent recurrence, and related documentation, with reference number 729021 in the subject line.

Who should pay attention

  • online sellers of men’s sexual-health products
  • marketplace and e-commerce compliance teams
  • consumers buying prostate or erectile products online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk